Navigation Links
HIV Treatments Improve Health, but Nutritional Issues Remain

most one fourth of the NFHL participants had metabolic syndrome, although this is lower than the incidence of metabolic syndrome in the population as a whole,” says Jacobson. “Strikingly, 77 percent of people with metabolic syndrome in the NFHL study had the same two defining characteristics, low HDL cholesterol and hypertriglyceridemia.”

“It appears that HIV viral load and metabolic syndrome are associated, as people with both HIV and metabolic syndrome were likely to have a clinically relevant increase in viral load within six months of developing components of metabolic syndrome,” says Gorbach, who is a professor at Tufts University School of Medicine and at the Friedman School of Nutrition Science and Policy at Tufts. “An increased viral load is also linked to a decrease in HDL cholesterol levels, so this may be what drives metabolic syndrome in people with HIV.”

Both HAART and non-HAART users in the NFHL study had a higher incidence of low HDL than the NHANES population. However, only HAART users demonstrated high triglyceride levels, leading the researchers to conclude that certain anti-retroviral therapies may also increase the risk for components of metabolic syndrome.

“We have seen that people with HIV have an increased prevalence of two of the characteristics of metabolic syndrome, components that are also associated with cardiovascular disease (CVD) and diabetes,” says Wanke, a professor at Tufts University School of Medicine. “People with HIV are also living longer due to advances in treatment, and their risk of CVD and diabetes increases with age as it does in the general population. Since people with HIV are already at higher risk for low HDL cholesterol and hypertriglyceridemia, it might be important for health care providers to monitor risk for metabolic syndrome, as these risk factors may increase the likelihood of additional medical complications.”

Using the same NHFL population, Clara Jones, MD, MP
'"/>




Page: 1 2 3

Related medicine news :

1. New Gene Identification Help Asthma Treatments
2. Comparing Psoriasis Treatments
3. Effectiveness Of Infertility Treatments Questioned
4. Cancer Treatments Fall Short Of Targets
5. LASIK Treatments Still To Reach Common Man
6. Asian Alternative Treatments For Cancer On The Rise In Europe
7. All Specialty Care Treatments Will Be Offered At Belle Vue.
8. Mobilizing Stem Cells at the Injured Site Using Hyperbaric Oxygen Treatments.
9. Personalized Treatments For Obesity Planned
10. Terahertz Imaging Promises To Revolutionize Breast Cancer Treatments
11. Call for Volunteers in Research on Asthma Treatments
Post Your Comments:
(Date:9/4/2008)... may be shortchanging their golden years by tappin...iversity of Illinois expert who has studied the fe..., More than three of every four Americans trim th...iming benefits early, a choice many might forego i... consequences, law professor Richard L. Kaplan say...
(Date:9/4/2008)...ncology contract research organization, has publis...uanced Approach to Get Into the Clinic Faster.&quo...al research scientist with 35 years of experience,...mmonly viewed as straightforward investigations ru...rue integration with preclinical, regulatory and c...
(Date:9/4/2008)...NORWICH, England and ONGAR, Ireland,Sept. 4 /PRNe...ofield Media,Europe Ltd, announced on the 29th Aug... publication from Silverdog Publishing., Health a... the iconic,Health and Safety at Work Act 1974 and.... It has been relied upon by blue-chip corporates,...
(Date:9/4/2008)...-FirstCall/ -- ULURU Inc. (Amex:,ULU) today announ...Weisel,Partners Healthcare Conference at 3:15 p.m....out ULURU Inc.:, ULURU Inc. is an emerging specia...ent of a portfolio of wound management, plastic su...nd consumers improved clinical,outcomes through co...
Breaking Medicine News(10 mins):Health News:New guide explores making the most of Social Security 2Health News:New guide explores making the most of Social Security 3Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 2Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 3Health News:Schofield Publishing Enters the Newsletter Market 2
...arch that was published in Nature, certain genetic...dworm Caenorhabditis// elegans also decrease the g...nderstand why cancer risk increases as we grow old...or cancer therapeutics. Professor Cynthia Kenyon ...
... Andaman and Nicobar Islands who lost their parent...et to get over their trauma, says a new report.// ...committee comprising researchers Shivani Chaudhary...large number of children continue to suffer becaus...
...e University of Florida (UF) have shown that ordin... is of self-renewal //and adaptability normally as...e UF's McKnight Brain Institute in their writing, ...Development, explained in detail as to how they us...
...eek send education material on informed financial ...de in an effort to encourage// greater openness be...dical care and procedures. Informed financial cons...f time of the medical fee they have to pay, as wel...
Other Medicine News:Health News:Long-life genes - A new way to combat cancer… 2Health News:Long-life genes - A new way to combat cancer… 3Health News:Post-tsunami trauma still haunts children 2Health News:Human Brain Cells Might Have The Self Potential For Healing 2Health News:Human Brain Cells Might Have The Self Potential For Healing 3Health News:AMA Urges Doctors to be Upfront about Fees 2
(Date:9/3/2008)...G, Md., Sept. 3 /- Panacea Pharmaceut...atent Number 7,413,737 covering,antibodies against...AH), a,proprietary human cancer biomarker and ther... collaboration with the Massachusetts Institute of...wide rights to this patent,for development of huma...
(Date:9/3/2008)... Trial Reconfirms Strong Evidence Pycnogenol(R) Lo...ffect on Joints Following Cessation .... 3 /- According to the Center for,Di...on type of arthritis,is on the rise. A new study ...search, reveals Pycnogenol(R), bark extract from t...
(Date:9/2/2008)...ember 3 /-, - This Analysi...e Risk,of Stroke by 34% in Patients With Atrial Fi...eated by Antithrombotic Therapy, The results of a...dy,were presented today at the clinical trial upda...ongress 2008, in Munich, Germany. Previous results...
(Date:9/2/2008)...y Meets Primary Bone Mineral Density and Secondary... Company to Host Conference Call and Webcast Wedn...0 am ET / 5:30 am PT, SAN DIEGO, Sept. 2 /PRNewsw...sdaq: NBIX ) today announced positive safety and ...trial using its proprietary, orally-active,nonpept...
Breaking Medicine Technology:Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 2Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 3Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 4Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 2Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 3Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 4Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 2Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 3Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 4Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 5Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 6Reflecting on the social implications of human genetics research past present and future 2780 1Reflecting on the social implications of human genetics research past present and future 2780 2Analysis Highlights Economic Contribution of Hospitals to Communities 16090 1Analysis Highlights Economic Contribution of Hospitals to Communities 16090 2Quest Diagnostics to Release First Quarter 2008 Financial Results and Conduct Quarterly Investor Conference Call 16088 1Quest Diagnostics to Release First Quarter 2008 Financial Results and Conduct Quarterly Investor Conference Call 16088 2VA Announces SGLI and VGLI Premium Reductions 16086 1VA Announces SGLI and VGLI Premium Reductions 16086 2
...nistration show potential for,new option to improv...07 /PRNewswire-FirstCall/ -- Millennium,Pharmaceut...sitive,data for VELCADE, the market-leading therap... received at least one prior therapy.,These data i...ous,(SC) administration of VELCADE, a new option u...
...llicular Lymphoma Reported,Today at ASCO Annual Me... GlaxoSmithKline plc,announced today long-term eff...eek course of frontline treatment with the BEXXAR(...31 Tositumomab) in,76 patients with newly diagnose.... This regimen was found to induce durable clinica...
Other Medicine Technology:New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 2New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 3New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 4New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 5New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 6New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 78-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 28-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 38-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 48-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 58-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 68-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 7
...tional reference laboratory and a worldwide leader.... ARUP offers an extensive test menu of highly com...omic pathology. Owned by the University of Utah, A...f the nation's university teaching hospitals and c...
...tional reference laboratory and a worldwide leader.... ARUP offers an extensive test menu of highly com...omic pathology. Owned by the University of Utah, A...f the nation's university teaching hospitals and c...
...tional reference laboratory and a worldwide leader.... ARUP offers an extensive test menu of highly com...omic pathology. Owned by the University of Utah, A...f the nation's university teaching hospitals and c...
...tional reference laboratory and a worldwide leader.... ARUP offers an extensive test menu of highly com...omic pathology. Owned by the University of Utah, A...f the nation's university teaching hospitals and c...
Medicine Products: